Predictors of Willingness of the General Public to Receive a Second COVID-19 Booster Dose or a New COVID-19 Vaccine: A Cross-Sectional Study in Greece

Galanis, Petros; Vraka, Irène; Katsiroumpa, Aglaia; Σίσκου, Όλγα; Konstantakopoulou, Olympia; Κατσούλας, Θεόδωρος; Mariolis‐Sapsakos, Theodoros; Kaitelidou, Daphne

doi:10.20944/preprints202206.0024.v1

Cited by 12 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the crude regression analysis indicated that fear of adverse effects of the vaccine is one of the reasons for a lower IBV. This aligns with many studies that concluded that concern about adverse effects was the main factor for refusal or hesitancy to receive a booster dose ( Qin et al, 2022 ; Rzymski, Poniedziałek & Fal, 2021 ; Folcarelli et al, 2022 ; Galanis et al, 2022 ; Lounis et al, 2022 ). However, in the adjusted model, no such association was observed, possibly because this effect may have been overshadowed by the recommendation of physicians and other health professionals.…”

Section: Discussionsupporting

confidence: 84%

“…Studies conducted in China ( Qin et al, 2022b ; Tung et al, 2019 ; Hu et al, 2022 ), Malaysia ( Abdullah, Ching & Ali, 2023 ) and Czech Republic ( Klugar et al, 2021 ), as well as a systematic review ( Abdelmoneim et al, 2022 ), indicated that the perceived efficacy or effectiveness of vaccines was associated with IBV of the booster dose. On the other hand, studies conducted in China ( Lai et al, 2021 ; Qin et al, 2022 ) and countries such as Poland ( Rzymski, Poniedziałek & Fal, 2021 ), Italy ( Folcarelli et al, 2022 ), Greece ( Galanis et al, 2022 ), and Algeria ( Lounis et al, 2022 ) reported that the reasons for refusing to receive the booster dose were uncertainty about its efficacy and the perception that an additional dose was not necessary. It should also be considered that these studies were conducted at different times during the COVID-19 pandemic, which could result in variations in the results, as the perception of the population may have changed over time.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with intention to be vaccinated with the COVID-19 booster dose: a cross-sectional study in Peru

Camacho-Neciosup,

Balcazar-Huaman,

Alvarez-Vilchez

et al. 2024

PeerJ

View full text Add to dashboard Cite

Introduction The pandemic of COVID-19 continues to impact people worldwide, with more than 755 million confirmed cases and more than 6.8 million reported deaths. Although two types of treatment, antiviral and immunomodulatory therapy, have been approved to date, vaccination has been the best method to control the spread of the disease. Objective To explore factors associated with the intention to be vaccinated with the COVID-19 booster dose in Peru. Material and Methods Cross-sectional study, using virtual and physical surveys of adults with two or more doses of COVID-19 vaccine, where the dependent variable was the intention to be vaccinated (IBV) with the booster dose. We calculated prevalence ratios with 95% confidence intervals, using generalized linear models of the Poisson family with robust varying, determining associations between sociodemographic, clinical, and booster dose perception variables. Results Data from 924 adults were analyzed. The IBV of the booster doses was 88.1%. A higher prevalence was associated with being male (aPR = 1.05; 95% CI [1.01–1.10]), having a good perception of efficacy and protective effect (PR = 3.69; 95% CI [2.57–5.30]) and belonging to the health sector (PR = 1.10; 95% CI [1.04–1.16]). There was greater acceptance of the recommendation of physicians and other health professionals (aPR = 1.40; 95% CI [1.27–1.55]). Conclusions Factors associated with higher IBV with booster dose include male gender, health sciences, physician recommendation, and good perception of efficacy.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Factors associated with intention to be vaccinated with the COVID-19 booster dose: a cross-sectional study in Peru

Camacho-Neciosup,

Balcazar-Huaman,

Alvarez-Vilchez

et al. 2024

PeerJ

View full text Add to dashboard Cite

show abstract

“…This study found a positive association of side-effects with female sex, younger age, and brand of the vaccine. (35) In our study, we did not nd an association between age and side-effects. Consistent with existing literature, we found a strong association of our outcome with female sex, and a weak association with vaccine dose, and a recent COVID-19 infection.…”

Section: Discussioncontrasting

confidence: 64%

Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: A prospective cohort study among primary health care providers in Belgium.

Domen,

Abrams,

Digregorio

et al. 2024

Preprint

View full text Add to dashboard Cite

Background COVID-19 vaccine effectiveness declines months after vaccination. Therefore, it is likely that during the next few years, people may be repeatedly offered a booster vaccine to enhance humoral immunity levels. A growing number of people are questioning whether the benefits of a booster vaccine outweigh the side-effects. Objective This study aims (1) to identify the most frequently reported side-effects after different doses of COVID-19 mRNA vaccines, (2) and the longest lasting symptoms; and (3) to predict the likelihood of having moderate-to-severe side-effects after a booster COVID-19 mRNA vaccine given individual- and vaccine-specific characteristics. Design, setting, and participants : Secondary analysis of a prospective cohort study in primary health care providers (PHCPs) in Belgium conducted between December 2020 and December 2021, and in February-March 2023. Methods In nine subsequent surveys over a period of 2 years vaccine dose-number and side-effects after COVID-19 vaccines were collected. A Generalized Estimation Equations approach on the data of the first and second booster dose was used to investigate the probability of having moderate-to-severe side-effects after mRNA booster vaccination. Predictive performance of a binary classifier was assessed by looking at discrimination (i.e., quantified in terms of the area under the receiver operating characteristic curve). The final prediction model was validated using data with regard to the third booster by assessing misclassification rate, sensitivity and specificity. Results In total, 11% of the PHCPs had moderate-to-severe side-effects after their booster COVID-19 mRNA vaccine. The most common side-effects of COVID-19 mRNA doses included fatigue, local pain at the injection site, general pains, and headache. These side-effects typically lasted for a median of 1 to 2 days. The final model included five predictors: sex, alcohol consumption, history of moderate-to-severe side-effects after any previous dose, recent COVID-19 infection, and the booster dose-number (first, second). Having experienced moderate-to-severe side-effects after any previous dose was the strongest predictor of moderate-to-severe side-effects following an mRNA vaccine booster, with an odds ratio (OR) of 3.64 (95% CI: 2.80–4.75). The OR for female sex was 1.49 (95% CI: 1.21–1.84) implying that females have a higher odds of moderate-to-severe side-effects following booster vaccination. The differences in effect for booster dose-number, alcohol consumption and recent COVID-19 infection was not significant. Conclusion and Relevance: COVID-19 mRNA booster vaccination implies a low prevalence of moderate-to-severe side-effects among PHCPs, with a short median duration of symptoms if any. The strongest predictors are a history of moderate-to-severe side-effects after any previous dose and being female. These reassuring findings can help addressing concerns about booster vaccination and encourage their uptake. Trial Registration: NCT04779424

show abstract

“…A study found that men's desire was 2.5 times higher than women's (23). Female desire may be lower due to psychological gender differences (24), aversion to novel medical technology (25), and belief in vaccine-fertility myths shared on social media (26,27). The highest willingness to receive the vaccine was observed in the age group over 60.…”

Section: Discussionmentioning

confidence: 99%

“…According to a review study, eight out of 12 studies reported a significantly higher likelihood of older individuals accepting the first booster dose of the vaccine (23). The greater tendency in older adults may be due to the high probability of getting a severe form of the disease, hospitalization, and mortality due to COVID-19 (24). People with an underlying condition were more likely to get a booster dosage, while unwillingness in healthy individuals was also found (4).…”

Section: Discussionmentioning

confidence: 99%

The Relationship Between Risk Communication and Willingness to Receive Booster Doses of COVID-19 Vaccines

Sepehrian,

Mohammadi Bolbanabad,

Taymoori

et al. 2023

J Kermanshah Univ Med Sci

View full text Add to dashboard Cite

Background: Identifying factors associated with willingness to receive a booster dose of COVID-19 vaccines and risk communication are essential to control the pandemic. Objectives: The study aimed to evaluate the relationship between risk communication and willingness to receive booster doses of COVID-19 vaccines. Methods: This cross-sectional study was conducted on 746 over 18 years old adults in Kermanshah, Iran, on October 2022 using random cluster sampling from 396,000 members of the general population who had not received a COVID-19 booster dose. Required data were collected using an online questionnaire from people who met the study requirements and analyzed via SPSS software version 22. Results: A total of 746 participants were between the ages of 40 and 59, 374.0% had a history of underlying disease, and 61.9% received two doses of the Sinopharm vaccine. About 36.3% were willing to accept booster dosages, and men, older adults, and those with underlying diseases were more likely to receive booster vaccinations. The most influential sources of information were social networks and television. There was a positive and significant correlation between risk communication and willingness to receive booster vaccine doses (P > 0.05). The average risk communication scores were higher among those more likely to receive a booster dose. Conclusions: Health policymakers should pay more attention to risk communication in designing multi-component interventions and producing appropriate and authentic content in social networks to increase the general population’s acceptance of vaccine booster doses.

show abstract

Predictors of Willingness of the General Public to Receive a Second COVID-19 Booster Dose or a New COVID-19 Vaccine: A Cross-Sectional Study in Greece

Cited by 12 publications

References 43 publications

Factors associated with intention to be vaccinated with the COVID-19 booster dose: a cross-sectional study in Peru

Factors associated with intention to be vaccinated with the COVID-19 booster dose: a cross-sectional study in Peru

Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: A prospective cohort study among primary health care providers in Belgium.

The Relationship Between Risk Communication and Willingness to Receive Booster Doses of COVID-19 Vaccines

Contact Info

Product

Resources

About